Competing endogenous RNA interplay in cancer: mechanism, methodology, and perspectives

Tumor Biology

Volumn 36, Issue 2, 2015, Pages 479-488

  Cheng, Dong Liang ^a   Xiang, Yuan Yuan ^b   Ji, Li Juan ^c   Lu, Xiao Jie ^d  

^a HUBEI UNIVERSITY OF MEDICINE   (China)

^b Huai'an Maternal and Child Health Care Center   (China)

^c Second People's Hospital of Huai'an   (China)

^d TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Cancer; ceRNA; miRNA; miRNA response elements

Indexed keywords

CIRCULAR RNA; COMPETING ENDOGENOUS RNA; LONG UNTRANSLATED RNA; MESSENGER RNA; MICRORNA; RNA; RNA BINDING PROTEIN; UNCLASSIFIED DRUG; UNTRANSLATED RNA; RNA, CIRCULAR;

BINDING AFFINITY; BREAST CANCER; CARCINOGENESIS; CELLULAR DISTRIBUTION; ENDOMETRIUM CANCER; GENE EXPRESSION; GENE FUNCTION; HUMAN; LIVER CANCER; LUNG CANCER; NEOPLASM; NONHUMAN; OVERALL SURVIVAL; PATHOGENESIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN SECONDARY STRUCTURE; PSEUDOGENE; REVIEW; RNA EDITING; STOMACH CANCER; TUMOR GROWTH; GENE REGULATORY NETWORK; GENETICS; PATHOLOGY;

GENE REGULATORY NETWORKS; HUMANS; MICRORNAS; NEOPLASMS; RNA; RNA, MESSENGER; RNA, UNTRANSLATED; RNA-BINDING PROTEINS;

EID: 84925515962     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3093-z     Document Type: Review

References (72)

1. ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489:57–74.
2. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136:215–33.
3. Poliseno L, Salmena L, Zhang J, Carver B, Haveman WJ, Pandolfi PP. A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature. 2010;465:1033–8.
4. Tay Y, Kats L, Salmena L, Weiss D, Tan SM, Ala U, et al. Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. Cell. 2011;147:344–57.
5. Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell. 2011;146:353–8.
6. Li N, Flynt AS, Kim HR, Solnica-Krezel L, Patton JG. Dispatched Homolog 2 is targeted by miR-214 through a combination of three weak microRNA recognition sites. Nucleic Acids Res. 2008;36(13):4277–85.
7. Brennecke J, Stark A, Russell RB, Cohen SM. Principles of microRNA-target recognition. PLoS Biol. 2005;3(3):e85.
8. Wang B, Love TM, Call ME, Doench JG, Novina CD. Recapitulation of short RNA-directed translational gene silencing in vitro. Mol Cell. 2006;22:553–60.
9. Chi SW, Zang JB, Mele A, Darnell RB. Argonaute HITS-CLIP decodes microRNA-mRNA interaction maps. Nature. 2009;460:479–86.
10. Qiu MT, Hu JW, Yin R, Xu L. Long noncoding RNA: an emerging paradigm of cancer research. Tumour Biol. 2013;34(2):613–20.
11. Li CH, Chen Y. Targeting long non-coding RNAs in cancers: progress and prospects. Int J Biochem Cell Biol. 2013;45(8):1895–910.
12. Deng K, Guo X, Wang H, Xia J. The lncRNA-MYC regulatory network in cancer. Tumour Biol. 2014;35(10):9497–503.
13. Penny GD, Kay GF, Sheardown SA, Rastan S, Brockdorff N. Requirement for Xist in X chromosome inactivation. Nature. 1996;379:131–7.
14. Wang J, Liu X, Wu H, Ni P, Gu Z, Qiao Y, et al. CREB up-regulates long non-coding RNA, HULC expression through interaction with microRNA-372 in liver cancer. Nucleic Acids Res. 2010;38:5366–83.
15. Liu XH, Sun M, Nie FQ, Ge YB, Zhang EB, Yin DD, et al. Lnc RNA HOTAIR functions as a competing endogenous RNA to regulate HER2 expression by sponging miR-331-3p in gastric cancer. Mol Cancer. 2014;13:92.
16. Zhou X, Gao Q, Wang J, Zhang X, Liu K, Duan Z. Linc-RNA-RoR acts as a "sponge" against mediation of the differentiation of endometrial cancer stem cells by microRNA-145. Gynecol Oncol. 2014;133:333–9.
17. Xiao-Jie L, Ai-Mei G, Li-Juan J, Jiang X. Pseudogene in cancer: real functions and promising signature. J Med Genet. 2015;52(1):17–24.
18. Yu G, Yao W, Gumireddy K, Li A, Wang J, Xiao W, et al. Pseudogene PTENP1 Functions as a Competing Endogenous RNA to Suppress Clear-Cell Renal Cell Carcinoma Progression. Mol Cancer Ther. 2014;13(12):3086–97.
19. Capel B, Swain A, Nicolis S, Hacker A, Walter M, Koopman P, et al. Circular transcripts of the testis-determining gene Sry in adult mouse testis. Cell. 1993;73:1019–30.
20. Hansen TB, Jensen TI, Clausen BH, Bramsen JB, Finsen B, Damgaard CK, et al. Natural RNA circles function as efficient microRNA sponges. Nature. 2013;495(7441):384–8.
21. Fang L, Du WW, Yang X, Chen K, Ghanekar A, Levy G, et al. Versican 3ʹ-untranslated region (3ʹ-UTR) functions as a ceRNA in inducing the development of hepatocellular carcinoma by regulating miRNA activity. FASEB J. 2013;27:907–19.
22. Wang L, Guo ZY, Zhang R, Xin B, Chen R, Zhao J, et al. Pseudogene OCT4-pg4 functions as a natural micro RNA sponge to regulate OCT4 expression by competing for miR-145 in hepatocellular carcinoma. Carcinogenesis. 2013;34:1773–81.
23. Lee DY, Jeyapalan Z, Fang L, Yang J, Zhang Y, Yee AY, et al. Expression of versican 3ʹ-untranslated region modulates endogenous microRNA functions. PLoS ONE. 2010;5:e13599.
24. Jeyapalan Z, Deng Z, Shatseva T, Fang L, He C, Yang BB. Expression of CD44 30-untranslated region regulates endogenous microRNA functions in tumorigenesis and angiogenesis. Nucleic Acids Res. 2011;39:3026–41.
25. Rutnam ZJ, Yang BB. The non-coding 3' UTR of CD44 induces metastasis by regulating extracellular matrix functions. J Cell Sci. 2012;125:2075–85.
26. Yang J, Li T, Gao C, Lv X, Liu K, Song H, et al. FOXO1 3'UTR functions as a ceRNA in repressing the metastases of breast cancer cells via regulating miRNA activity. FEBS Lett. 2014;588:3218–24.
27. Kumar MS, Armenteros-Monterroso E, East P, Chakravorty P, Matthews N, Winslow MM, et al. HMGA2 functions as a competing endogenous RNA to promote lung cancer progression. Nature. 2014;505:212–7.
28. Liu K, Guo L, Guo Y, Zhou B, Li T, Yang H, et al. AEG-1 3'-untranslated region functions as a ceRNA in inducing epithelial-mesenchymal transition of human non-small cell lung cancer by regulating miR-30a activity. Eur J Cell Biol. 2015;94(1):22–31.
29. Karreth FA, Tay Y, Perna D, Ala U, Tan SM, Rust AG, et al. In vivo identification of tumor- suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma. Cell. 2011;147:382–95.
30. Sumazin P, Yang X, Chiu HS, Chung WJ, Iyer A, Llobet-Navas D, et al. An extensive microRNA-mediated network of RNA-RNA interactions regulates established oncogenic pathways in glioblastoma. Cell. 2011;147:370–81.
31. Ebert MS, Sharp PA. Emerging roles for natural microRNA sponges. Curr Biol. 2010;20:R858–61.
32. Mukherji S, Ebert MS, Zheng GXY, Tsang JS, Sharp PA, van Oudenaarden A. MicroRNAs can generate thresholds in target gene expression. Nat Genet. 2011;43:854–9.
33. Figliuzzi M, Marinari E, De Martino A. MicroRNAs as a selective channel of communication between competing RNAs: a steady-state theory. Biophys J. 2013;104:1203–13.
34. Pal S, Gupta R, Davuluri RV. Alternative transcription and alternative splicing in cancer. Pharmacol Ther. 2012;136:283–94.
35. Zhou X, Li X, Cheng Y, Wu W, Xie Z, Xi Q. BCLAF1 and its splicing regulator SRSF10 regulate the tumorigenic potential of colon cancer cells. Nat Commun. 2014. doi:10.1038/ncomms5581.
36. Xu Y, Gao XD, Lee JH, Huang H, Tan H, Ahn J, et al. Cell type-restricted activity of hnRNPM promotes breast cancer metastasis via regulatingalternative splicing. Genes Dev. 2014;28:1191–203.
37. Venables JP, Klinck R, Koh C, Gervais-Bird J, Bramard A, Inkel L, et al. Cancer-associated regulation of alternative splicing. Nature Struct Mol Biol. 2009;16:670–6.
38. Mayr C, Bartel DP. Widespread shortening of 3ʹUTRs by alternative cleavage and polyadenylation activates oncogenes in cancer cells. Cell. 2009;138:673–84.
39. Lembo A, Di Cunto F, Provero P. Shortening of 3ʹUTRs correlates with poor prognosis in breast and lung cancer. PLoS ONE. 2012;7:e31129.
40. Lau CC, Sun T, Ching AK, He M, Li JW, Wong AM, et al. Viral-human chimeric transcript predisposes risk to liver cancer development and progression. Cancer Cell. 2014;25:335–49.
41. Park K, Dalton JT, Narayanan R, Barbieri CE, Hancock ML, Bostwick DG, et al. TMPRSS2:ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia. J Clin Oncol. 2014;32:206–11.
42. Li F, Feng Y, Fang R, Fang Z, Xia J, Han X, et al. Viral-human chimeric transcript predisposes risk to liver cancer development and progression. Cell Res. 2012;22:928–31.
43. Almeida MI, Reis RM, Calin GA. Decoy activity through microRNAs: the therapeutic implications. Expert Opin Biol Ther. 2012;12:1153–9.
44. Sabarinathan R, Wenzel A, Novotny P, Tang X, Kalari KR, Gorodkin J. Transcriptome-wide analysis of UTRs in non-small cell lung cancer reveals cancer-related genes with SNV-induced changes on RNA secondary structure and miRNA target sites. PLoS One. 2014;9(1):e82699.
45. Maas S. Posttranscriptional recoding by RNA editing. Adv Protein Chem Struct Biol. 2012;86:193–224.
46. Kawahara Y, Megraw M, Kreider E, Iizasa H, Valente L, Hatzigeorgiou AG, et al. Frequency and fate of microRNA editing in human brain. Nucleic Acids Res. 2008;36:5270–80.
47. Levanon EY, Eisenberg E, Yelin R, Nemzer S, Hallegger M, Shemesh R, et al. Systematic identification of abundant A-to-I editing sites in the human transcriptome. Nature Biotechnol. 2004;22:1001–5.
48. Young LE, Moore AE, Sokol L, Meisner-Kober N, Dixon DA. The mRNA stability factor HuR inhibits microRNA-16 targeting of COX-2. Mol Cancer Res. 2012;10:167–80.
49. Epis MR, Barker A, Giles KM, Beveridge DJ, Leedman PJ. The RNA-binding protein HuR opposes the repression of ERBB-2 gene expression by microRNA miR-331–3p in prostate cancer cells. J Biol Chem. 2011;286:41442–54.
50. Kim HH, Kuwano Y, Srikantan S, Lee EK, Martindale JL, Gorospe M. HuR recruits let-7/RISC to repress c-Myc expression. Genes Dev. 2009;23:1743–8.
51. Ala U, Karreth FA, Bosia C, Pagnani A, Taulli R, Léopold V, et al. Integrated transcriptional and competitive endogenous RNA networks are cross-regulated in permissive molecular environments. Proc Natl Acad Sci U S A. 2013;110:7154–9.
52. Li JH, Liu S, Zhou H, Qu LH, Yang JH. starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein–RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 2014;42:D92–7. doi:10.1093/nar/gkt1248.
53. Sarver AL, Subramanian S. Competing endogenous RNA database. Bioinformation. 2012;8:731–3.
54. Miranda KC, Huynh T, Tay Y, Ang YS, Tam WL, Thomson AM, et al. A pattern-based method for the identification of microRNA binding sites and their corresponding heteroduplexes. Cell. 2006;126:1203–17.
55. Hafner M, Landthaler M, Burger L, Khorshid M, Hausser J, Berninger P, et al. Transcriptome-wide identification of RNA-binding protein and microRNA target sites by PAR-CLIP. Cell. 2010;141:129–41.
56. Thomson DW, Bracken CP, Goodall GJ. Experimental strategies for microRNA target identification. Nucleic Acids Res. 2011;39:6845–53.
57. Yoon JH, Srikantan S, Gorospe M. MS2-TRAP (MS2-tagged RNA affinity purification): tagging RNA to identify associated miRNAs. Methods. 2012;58:81–7.
58. Schug J, McKenna LB, Walton G, Hand N, Mukherjee S, Essuman K, et al. Dynamic recruitment of microRNAs to their mRNA targets in the regenerating liver. BMC Genomics. 2013. doi:10.1186/1471-2164-14-264.
59. Memczak S, Jens M, Elefsinioti A, Torti F, Krueger J, Rybak A, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature. 2013;495:333–8.
60. Jeck WR, Sorrentino JA, Wang K, Slevin MK, Burd CE, Liu J, et al. Circular RNAs are abundant, conserved, and associated with ALU repeats. RNA. 2013;19:141–57.
61. Salzman J, Gawad C, Wang PL, Lacayo N, Brown PO. Circular RNAs are the predominant transcript isoform from hundreds of human genes in diverse cell types. PLoS ONE. 2012;7:e30733. doi:10.1371/journal.pone.0030733.
62. Taulli R, Loretelli C, Pandolfi PP. From pseudo-ceRNAs to circ-ceRNAs: a tale of cross-talk and competition. Nature Struct Mol Biol. 2013;20:541–3.
63. Wilusz JE, Sharp PA. Molecular biology. A circuitous route to noncoding RNA. Science. 2013;340:440–1.
64. Tollervey D. Molecular biology: RNA lost in translation. Nature. 2006;440:425–6.
65. Dey N, Das F, Ghosh-Choudhury N, Mandal CC, Parekh DJ, Block K, et al. microRNA-21 governs TORC1 activation in renal cancer cell proliferation and invasion. PLoS One. 2012;7:e37366. doi:10.1371/journal.pone.0037366.
66. Xu G, Zhang Y, Wei J, Jia W, Ge Z, Zhang Z, et al. MicroRNA-21 promotes hepatocellular carcinoma HepG2 cell proliferation through repression of mitogen activated protein kinase-kinase 3. BMC Cancer. 2013. doi:10.1186/1471-2407-13-469.
67. Mandal CC, Ghosh-Choudhury T, Dey N, Choudhury GG, Ghosh-Choudhury N. miR-21 is targeted by omega-3 polyunsaturated fatty acid to regulate breast tumor CSF-1 expression. Carcinogenesis. 2012;33:1897–908.
68. Lin J, Teo S, Lam DH, Jeyaseelan K, Wang S. MicroRNA-10b pleiotropically regulates invasion, angiogenicity and apoptosis of tumor cells resembling mesenchymal subtype of glioblastoma multiforme. Cell Death Dis. 2012. doi:10.1038/cddis.2012.134.
69. Li Q, Li X, Guo Z, Xu F, Xia J, Liu Z, et al. MicroRNA-574-5p was pivotal for TLR9 signaling enhanced tumor progression via down-regulating checkpoint suppressor in human lung cancer. PLoS One. 2012;7:e48278.
70. Lin CW, Chang YL, Chang YC, Lin JC, Chen CC, Pan SH, et al. MicroRNA-135b promotes lung cancer metastasis by regulating multiple targets in the Hippo pathway and LZTS. Nat Commun. 2013. doi:10.1038/ncomms2876.
71. Liu Y, Cui H, Wang W, Li L, Wang Z, Yang S, et al. Construction of circular miRNA sponges targeting miR-21 or miR-221 and demonstration of their excellent anticancer effects on malignant melanoma cells. Int J Biochem Cell Biol. 2013;45:2643–50.
72. Dylla L, Jedlicka P. Growth-promoting role of the miR-106a–363 cluster in Ewing sarcoma. PLoS One. 2013;8:e63032.